医药稳健科研股策略:年化收益率（20.34%）
本策略精选医药生物行业中研发投入高、净利润快速增长、估值合理的优质股票。通过量化财务指标，筛选出具备持续成长潜力的标的，并定期轮动调仓，力求在医药行业中获取稳健收益。
概要
核心指标
- 累计收益率: 60.74%
- 年化收益率: 20.34%
- 基准收益率: 29.3%
- 阿尔法: 0.12
- 夏普比率: 0.74
- 最大回撤: 22.09%
源码
查看AI策略代码
绩效
持仓详情
|
当日收盘价 | 当日市值 | 浮动收益/浮动收益率
|
|||||
|---|---|---|---|---|---|---|---|
| 2026-05-15 | 九芝堂(000989.SZ) | 9.4308358707884 | 60428 | 10 | 8.79 | 531162.12 | -38724.43/-6.795% |
| 2026-05-15 | 亚宝药业(600351.SH) | 6.8720609876543 | 80800 | 10 | 6.55 | 529240 | -26022.53/-4.687% |
| 2026-05-15 | 海正药业(600267.SH) | 11.444485714286 | 49000 | 10 | 11.16 | 546840 | -13939.8/-2.486% |
| 2026-05-14 | 九芝堂(000989.SZ) | 9.4308358707884 | 60428 | 9 | 8.88 | 536600.64 | -33285.91/-5.841% |
| 2026-05-14 | 亚宝药业(600351.SH) | 6.8720609876543 | 80800 | 9 | 6.62 | 534896 | -20366.53/-3.668% |
| 2026-05-14 | 海正药业(600267.SH) | 11.444485714286 | 49000 | 9 | 11.52 | 564480 | 3700.2/0.66% |
| 2026-05-13 | 九芝堂(000989.SZ) | 9.7416504273504 | 58500 | 8 | 9.4 | 549900 | -19986.55/-3.507% |
| 2026-05-13 | 亚宝药业(600351.SH) | 6.8720609876543 | 80800 | 8 | 6.76 | 546208 | -9054.53/-1.631% |
| 2026-05-13 | 海正药业(600267.SH) | 11.444485714286 | 49000 | 8 | 11.47 | 562030 | 1250.2/0.223% |
| 2026-05-12 | 九芝堂(000989.SZ) | 9.7416504273504 | 58500 | 7 | 9.47 | 553995 | -15891.55/-2.789% |
交易详情
| 2026-05-14 | 九芝堂(000989.SZ) | 买 | 1928 | 9.1 | -5.2 | ¥0 | 0 |
| 2026-05-11 | 海正药业(600267.SH) | 买 | 400 | 11.56 | 4624 | ¥5 | 0 |
| 2026-05-11 | 亚宝药业(600351.SH) | 卖 | -200 | 7.01 | -1402 | ¥6.4 | 27.59 |
| 2026-05-11 | 九芝堂(000989.SZ) | 买 | 1500 | 9.69 | 14535 | ¥5 | 0 |
| 2026-04-29 | 德源药业(920735.BJ) | 买 | 2140 | 27.69 | -22.4 | ¥0 | 0 |
| 2026-04-29 | 桂林三金(002275.SZ) | 卖 | -41200 | 14.01 | -577212 | ¥750.38 | -1821.66 |
| 2026-04-29 | 力生制药(002393.SZ) | 卖 | -31256 | 16.84 | -526351.04 | ¥684.26 | -23427.07 |
| 2026-04-29 | 德源药业(920735.BJ) | 卖 | -20840 | 28 | -583520 | ¥758.58 | -7951.39 |
| 2026-04-29 | 海正药业(600267.SH) | 买 | 48600 | 11.44 | 555984 | ¥166.8 | 0 |
| 2026-04-29 | 亚宝药业(600351.SH) | 买 | 81000 | 6.87 | 556470 | ¥166.94 | 0 |
